IFRX InflaRx N.V.

3.49
-0.15  -4%
Previous Close 3.64
Open 3.64
Price To Book 0.66
Market Cap 91,107,340
Shares 26,105,255
Volume 363,274
Short Ratio
Av. Daily Volume 770,852
Stock charts supplied by TradingView

NewsSee all news

  1. InflaRx to Present at Upcoming J.P. Morgan Annual Healthcare Conference

    JENA, Germany, Jan. 09, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present at the

  2. InflaRx Reports Third Quarter 2019 Financial & Operating Results

    Recently announced results of open label extension part of SHINE Phase IIb study confirm potential of IFX-1 in Hidradenitis Suppurativa and warrant evaluation of future developmentCompany announces updated strategy with

  3. InflaRx Reports Positive Results from the Open Label Extension Part of the SHINE Study for IFX-1 in Hidradenitis Suppurativa

    70.6% of week 16 HiSCR responders maintain response throughout week 40 while 41.8% of non-responders become responders (total HiSCR rate = 56.3% at end of treatment)78.2% of OLE patients complete extension period and

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 initiation of dosing announced October 30, 2018.
IFX-1
ANCA-associated vasculitis/Granulomatosis With Polyangiitis (GPA)
Phase 2b data June 5, 2019 did not meet primary endpoint.
IFX-1
Hidradenitis Suppurativa
Phase 2a dosing of first patient announced June 13, 2019.
IFX-1
Pyoderma Gangraenosum (PG)
Phase 2 second trial initiation announced May 14, 2019.
IFX-1
ANCA-associated vasculitis (AAV)

Latest News

  1. InflaRx to Present at Upcoming J.P. Morgan Annual Healthcare Conference

    JENA, Germany, Jan. 09, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present at the

  2. InflaRx Reports Third Quarter 2019 Financial & Operating Results

    Recently announced results of open label extension part of SHINE Phase IIb study confirm potential of IFX-1 in Hidradenitis Suppurativa and warrant evaluation of future developmentCompany announces updated strategy with

  3. InflaRx Reports Positive Results from the Open Label Extension Part of the SHINE Study for IFX-1 in Hidradenitis Suppurativa

    70.6% of week 16 HiSCR responders maintain response throughout week 40 while 41.8% of non-responders become responders (total HiSCR rate = 56.3% at end of treatment)78.2% of OLE patients complete extension period and